Skip to content
PreclinicalResearch compound

RU58841 (PSK‑3841 / HMR‑3841)

Experimental skin-applied hair loss compound: mainly studied in animals, unproven in humans and not approved as a medicine.

Available at

The links above are labelled third-party affiliate links. MolekulaX does not sell and does not verify product quality.

RU58841 (PSK-3841 / HMR-3841) vial

DETAILED OVERVIEW

What is RU58841 (PSK-3841 / HMR-3841)?

RU58841 is an experimental compound that was designed to be applied to the skin against hair loss and acne. It has never been approved as a medicine anywhere. It is sold as a research chemical, with no official oversight or quality control, so its purity and composition are unverified. Bodybuilders also show interest in it as a way to prevent hair loss.

It does not stop DHT (dihydrotestosterone, a strong male hormone) from forming, as finasteride does. Instead it is thought to take the place of the hormone in the hair follicle, so that in theory the hormone cannot thin the hairs. This has mainly been studied in animals; its effect and safety in people are unproven. It should be strictly avoided in pregnancy and while breastfeeding, because a substance that blocks the action of male hormones could in theory harm the development of a male baby. In competitive sport it counts as banned.

Mechanism

Peripheral non-steroidal AR antagonist (NOT a 5AR inhibitor!) – scalp follicular AR binding blockade

Half-life

Topical minimal systemic absorption (claim), effect ~24 h

Onset

Scalp AR blockade immediate, hair stabilization 3-6 months (in vivo data sparse)

Legal status

Not approved; research chemical; considered banned in sport

Data console

Lab data

Androgenic:AnabolicN/A (AR antagonist, NOT AR agonist) – NOT AAS
AR bindingAR Ki ~0.5 nM (competitive antagonist, vs DHT ~5 nM…
Active half-lifeEffect ~24 h per application (claim, in vivo confirmation incomplete)
Detection windowWADA-accredited LC-MS/MS sparse data – research-chemical context urine detection 1-2 weeks post-topical application (in vivo data minimal)
AromatizationNo direct aromatization. Peripheral AR blockade → steroid axis NOT affected. (If absorbed systemically, AAS activity could be blocked – gyno-emphasizing risk feminization throughout the body.)
HepatotoxicityTopical low hepatic; in case of in vivo absorption, hepatic stress data are incomplete – caution in research-chemical context.

Safety

Side effects, stop signs, contraindications

Side effects · 6

  • Systemic feminizing effects with meaningful absorption: gynecomastia, reduced libido, erectile dysfunction, deteriorating sperm quality (the documented reason for the 1996 Phase II trial termination).
  • Local scalp irritation, itching, redness and contact dermatitis, mainly from the ethanol/propylene glycol vehicle (the most common, well-documented local effect).
  • NO long-term (6+ months) safety data: the endocrine and reproductive risks of chronic absorption are unknown because clinical development stopped at Phase II.
  • UGL/research-chemical sourcing risks: purity often <90%, unstable solution (potency <50% after 6 months at room temperature), vehicle-contamination allergy – the actual active content is not guaranteed.
  • Systemic AR blockade may suppress the anabolic effect of a concurrent AAS or SARM cycle if the compound is absorbed (receptor-level antagonism, not a mechanism conflict).
  • Mood symptoms: the Phase II monitoring protocol explicitly tracked IIEF-5 (sexual function) and PHQ-9 (depression), pointing to possible psychological complaints alongside sexual dysfunction.

Contraindications · 7

  • Contact with a pregnant partner: with systemic absorption the AR antagonist could theoretically disrupt fetal male sexual development – avoid when a partner is pregnant or planning pregnancy.
  • Fertility planning / active conception intent: not recommended for users planning children due to documented sperm-quality deterioration and sexual dysfunction.
  • Not indicated for prophylactic use in those not predisposed to AGA: with research-chemical status and absent safety evidence the risk-benefit balance is unjustifiable.
  • Topical only: NEVER take orally – the compound is intended for the scalp alone; ingestion drastically raises the risk of systemic AR blockade and feminizing effects.
  • Long-term chronic use (>12 months): in vivo safety data are missing and Phase II was halted precisely over systemic side effects – chronic use is not supported.
  • Prohibited for competitive athletes: banned by WADA under S1 (Other Anabolic Agents) as an AR modulator, both in and out of competition.
  • Damaged/inflamed scalp or ethanol/propylene glycol sensitivity: the vehicle can trigger contact dermatitis and increases systemic absorption when the skin barrier is compromised.

Related Performance Compounds

Same therapeutic category

Studies

Related research and clinical findings

Telegram

Have a question about RU58841 (PSK‑3841 / HMR‑3841)?

Reach out to an advisor on Telegram. Performance compounds are presented with a harm-reduction approach, based on peer-reviewed evidence.

Personalized consultation

Want a detailed conversation tailored to your data?

Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.

Fill out the form

~5–7 min · prep questionnaire · confidential · GDPR-compliant

MolekulaX Editorial Team·Source-verified · PubMed · FDA · EMA
Updated: October 14, 2026

The information here is for educational and scientific purposes only. Performance-enhancing compounds (AAS, prohormones, stimulants, doping agents) are illegal without prescription in Hungary and most of the EU, and carry serious health and legal risks. WADA bans them in competitive sport. This is NOT a usage guide, and we do not encourage any illegal use. If you do use them, medical supervision and regular bloodwork are ESSENTIAL. Severe endocrine, cardiovascular, hepatic and psychiatric side effects are possible.